New daily diabetes pill that helps with weight loss launches in UK pharmacies
Source: Guardian Health ↗
Foundayo will be available on private prescription, with pharmacists warning of counterfeit GLP-1 problem A new daily pill that treats diabetes and helps with weight loss will be available in UK pharmacies from Monday. Pharmacists said the move would be welcome for people who cannot use weight-loss jabs, but also issued a warning over the growing problem of fake, unlicensed or counterfeit versions of GLP-1 tablets . Orforglipron, known as Foundayo and made by the US pharmaceutical firm Eli Lilly, was authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) earlier this month. The UK is the first country in Europe to approve it, after approving another weight-loss pill in June. “The UK is the first country in Europe where Foundayo is now available,” said Khalil Asmar, the vice-president of cardiometabolic health at Lilly Northern Europe.
“We’re pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments.” The drug will initially be available through private prescription, with Eli Lilly saying it is working with the National Institute for Health and Care Excellence (Nice) on its assessment of Foundayo for a potential rollout on the health service in England. Th drug is licensed for people with a body mass index (BMI) of 30 or above, or those with a BMI of between 27 and 30 and at least one weight-related condition. It can also be used to improve blood sugar levels in patients with poorly controlled type 2 diabetes. The pill is taken once a day, at any time, with no food or water restrictions. Henry Gregg, the chief executive of the National Pharmacy Association, said: “This is another significant day with a second weight loss pill available from today in certain pharmacies.
This is particularly significant for patients who cannot or do not want to take an injectable medicine and could make weight-loss treatment available to a wider range of patients.” However, there are concerns about the marketing of fake, unlicensed or counterfeit drugs, which can be easier to produce in pill form than injectables. Last year, the MHRA seized £250,000-worth of unlicensed weight-loss pens and ingredients from a factory in Northampton, and Eli Lilly is suing various suppliers it accuses of participating in an illegal hidden market for its drugs. Patients are being urged to ensure that they access weight-loss treatments only through safe and regulated pharmacies. Gregg said: “There must now be a redoubling of efforts within government and the NHS to use pharmacies to make sure more eligible patients in clinical need can get weight loss treatments on the NHS, rather than the current postcode lottery that exists for weight management services via GPs.” The MHRA approved the first GLP-1 pill for weight loss, a tablet form of Wegovy, in June.
⚡ Effects Interpreter
🌍World Economylow impact
What this means for you
- ▶International capital can shift direction faster than headlines suggest.
- ▶Export-heavy economies could see demand wobble as buyers wait and watch.
🏙️Local Economylow impact
What this means for you
- ▶Your town's economy tends to catch up with big headlines eventually.
- ▶Everyday spending habits nearby might shift once the news sinks in.
🏦Rates & Banksmedium impact
What this means for you
- ▶Extra security steps at your bank are a likely, if mild, side effect here.
- ▶Lending criteria can quietly firm up as banks reassess their risk.
❤️Healthlow impact
What this means for you
- ▶Local wellbeing services are there precisely for moments when news feels overwhelming.
- ▶The strain, if any, tends to show up gradually in everyday life.
💷Wealthmedium impact
What this means for you
- ▶Fraud a story like this is a good nudge to review your account alerts.
- ▶Reporting anything suspicious quickly usually improves your chances of redress.
🏠Housinglow impact
What this means for you
- ▶Mortgage shoppers might find deals shift only slightly in the short term.
- ▶Housing supply and demand rarely turn on a single piece of news.
🌍 Effects for your country
The U.S.'s central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The U.S.'s economy is growing at 2.3% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the U.S.'s own central bank rate closely. With the U.S.'s unemployment at 4.4%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the U.S. depends more on local healthcare capacity than the figures above.
The UK's central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The UK's economy is growing at 0.8% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UK's own central bank rate closely. With the UK's unemployment at 5.6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the UK depends more on local healthcare capacity than the figures above.
France's central bank rate currently stands at 2%, so a global rates move like this could feed through to local borrowing costs. France's economy is growing at 0.9% with inflation at 1.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track France's own central bank rate closely. With France's unemployment at 7.9%, personal-finance effects like this land on a labour market that is already under strain. Health-system effects are harder to localise from economic indicators alone — the real impact in France depends more on local healthcare capacity than the figures above.
Romania's central bank rate currently stands at 6.5%, so a global rates move like this could feed through to local borrowing costs. Romania's economy is growing at 0.7% with inflation at 7.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track Romania's own central bank rate closely. With Romania's unemployment at 6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in Romania depends more on local healthcare capacity than the figures above.
The UAE's central bank rate currently stands at 3.65%, so a global rates move like this could feed through to local borrowing costs. The UAE's economy is growing at 3.1% with inflation at 2.5%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UAE's own central bank rate closely. Health-system effects are harder to localise from economic indicators alone — the real impact in the UAE depends more on local healthcare capacity than the figures above.